A detailed history of Dimensional Fund Advisors LP transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 1,046,200 shares of ITOS stock, worth $8.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,046,200
Previous 908,329 15.18%
Holding current value
$8.61 Million
Previous $13.5 Million 20.76%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$10.09 - $17.97 $1.39 Million - $2.48 Million
137,871 Added 15.18%
1,046,200 $10.7 Million
Q2 2024

Aug 09, 2024

BUY
$10.33 - $18.09 $1.21 Million - $2.12 Million
117,159 Added 14.81%
908,329 $13.5 Million
Q1 2024

May 10, 2024

BUY
$9.89 - $13.64 $178,287 - $245,888
18,027 Added 2.33%
791,170 $10.8 Million
Q4 2023

Feb 07, 2024

BUY
$8.57 - $11.06 $618,668 - $798,421
72,190 Added 10.3%
773,143 $8.47 Million
Q3 2023

Nov 09, 2023

BUY
$10.95 - $14.6 $1.34 Million - $1.79 Million
122,304 Added 21.14%
700,953 $7.68 Million
Q2 2023

Aug 09, 2023

BUY
$12.93 - $18.05 $2.11 Million - $2.94 Million
163,043 Added 39.23%
578,649 $7.66 Million
Q1 2023

May 12, 2023

BUY
$13.02 - $22.62 $3.26 Million - $5.67 Million
250,455 Added 151.65%
415,606 $5.66 Million
Q4 2022

Feb 09, 2023

BUY
$17.77 - $21.6 $2.62 Million - $3.18 Million
147,277 Added 823.97%
165,151 $3.23 Million
Q2 2022

Aug 12, 2022

SELL
$16.57 - $35.1 $1.83 Million - $3.87 Million
-110,216 Reduced 86.05%
17,874 $368,000
Q4 2021

Feb 09, 2022

BUY
$26.23 - $47.86 $2.08 Million - $3.8 Million
79,441 Added 163.29%
128,090 $5.96 Million
Q3 2021

Nov 12, 2021

BUY
$23.91 - $29.58 $1.16 Million - $1.44 Million
48,649 New
48,649 $1.31 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $293M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.